stockrow
Friday 6 November 2026
Export GLAS’s income statement to Excel — free account
Glass House Brands Inc.
GLAS Healthcare Drug Manufacturers Specialty & Generic
Glass House Brands Inc.’s revenue for fiscal 2025 (year ended December 2025) was $182.0 million, down 9.41% from fiscal 2024.
- Revenue
- −1.24%
- EPS
- −320.0%
- Free cash flow
- −123.4%
- Total debt
- −17.2%
Quarter to June 2026, against a year earlier
2.28
0.30
−11.63%
Follow GLAS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 161 | 201 | 182 | 177 | +6.4% | 195 | 236 | 272 | +14.3% | |
| Gross margin, % | — | — | — | — | — | — | — | 50.34 | 48.48 | 42.29 | 31.97 | (8.0) pt | ||||||
| EBT | — | — | — | — | — | — | — | (88) | 11 | (17) | (37) | (56.1%) | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (54.79) | 5.58 | (9.35) | (21.09) | +45.4 pt | ||||||
| Net income | — | — | — | — | — | — | — | (98) | 1 | (29) | (51) | (45.7%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 2.23 | 2.67 | 2.22 | 2.00 | (0.3%) | |||||
| Earnings | — | — | — | — | — | — | — | (1.62) | (0.21) | (0.55) | (0.76) | (41.7%) | ||||||
| Cash flow | — | — | — | — | — | — | — | 0.32 | 0.38 | 0.14 | (0.23) | (34.2%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.17) | (0.14) | (0.33) | (0.19) | +38.7% | ||||||
| Free cash flow | — | — | — | — | — | — | — | 0.15 | 0.24 | (0.19) | (0.41) | n/m | ||||||
| Book value | — | — | — | — | — | — | — | 0.93 | 1.03 | 1.00 | 0.82 | +3.7% | ||||||
| Shares, m | — | — | — | — | — | — | — | 72 | 75 | 82 | 85 | +6.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 2.17 | 3.98 | 1.14 | 2.1 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 5.62 | 8.83 | 2.79 | 4.8 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 2.25 | 4.30 | 1.35 | 2.2 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.00 | 24.96 | (50.40) | (6.51) | (8.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | 23 | 28 | 11 | (20) | (29.8%) | |||||
| Capex | — | — | — | — | — | — | — | (12) | (10) | (27) | (16) | +48.0% | ||||||
| Free cash flow | — | — | — | — | — | — | — | 11 | 18 | (16) | (37) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (38) | 0 | 30 | 18 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | 26 | 15 | 50 | 37 | +39.8% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 67 | 78 | 82 | 73 | +10.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (5.03) | (14.33) | (19.78) | (14.3) pt | |||||
| ROIC | — | — | — | — | — | — | — | (33.43) | 3.86 | (7.83) | (23.36) | +25.6 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | (21.33) | (56.40) | (74.02) | (56.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 374 | 426 | — | +13.9% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.54 | 0.43 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026
Glass House Brands Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ANIK Anika Therapeutics Inc. | $258.7M | — (loss-making) | 599× | +15.56% (above 0%: growing) | n/m | +61.58% (above 0%: growing) | 65.15% | 9.06% | Compare |
| BIOA BioAge Labs, Inc. | $254.3M | — (loss-making) | — (loss-making) | −85.49% (below 0%: shrinking) | n/m | −92.81% (below 0%: shrinking) | 100.00% | (12,554.03%) | Compare |
| LFCR Lifecore Biomedical, Inc. | $242.6M | — (loss-making) | — (loss-making) | −18.60% (below 0%: shrinking) | n/m | +27,684.00% (above 0%: growing) | 26.96% | (3.53%) | Compare |
| SIGA Siga Technologies Inc. | $213.4M | — (loss-making) | 60.8× | −49.45% (below 0%: shrinking) | −66.00% (below 0%: shrinking) | −75.95% (below 0%: shrinking) | 57.17% | 33.91% | Compare |
| ADCT ADC Therapeutics SA | $209.4M | — (loss-making) | — (loss-making) | +2.17% (above 0%: growing) | n/m | +50.98% (above 0%: growing) | 87.80% | (132.03%) | Compare |
| GLAS Glass House Brands Inc. | $172.7M | — (loss-making) | — (loss-making) | −1.24% (below 0%: shrinking) | n/m | −123.36% (below 0%: shrinking) | 33.54% | (6.37%) | |
| OGI Organigram Global Inc. | $131.1M | 2.0× | 1.6× | +49.28% (above 0%: growing) | n/m | −192.32% (below 0%: shrinking) | 39.16% | 5.04% | Compare |
| DERM Journey Medical Corporation | $121.4M | — (loss-making) | — (loss-making) | +23.33% (above 0%: growing) | n/m | −84.08% (below 0%: shrinking) | 66.81% | 2.46% | Compare |
| AKBA Akebia Therapeutics, Inc. | $117.9M | — (loss-making) | — (loss-making) | −37.20% (below 0%: shrinking) | n/m | −94.20% (below 0%: shrinking) | 82.76% | (31.06%) | Compare |
| Median of peers | $211.4M | — | 60.8× | −8.21% | — | −80.01% | 65.98% | (0.53%) |